Can Zepbound (tirzepatide) cause dizziness, and how should it be evaluated and managed in a patient who develops it?

Zepbound (Tirzepatide) and Dizziness

Zepbound can cause dizziness, and this side effect requires clinical attention, particularly in patients ≤60 years old who appear to be at higher risk. While dizziness is not listed among the most common gastrointestinal side effects (nausea, vomiting, diarrhea) emphasized in current guidelines 1, 2, recent meta-analysis data demonstrates a statistically significant 64% increased risk of dizziness with tirzepatide compared to placebo 3.

Evidence for Dizziness Risk

The most robust evidence comes from a 2025 meta-analysis of 12 RCTs involving 10,615 patients with type 2 diabetes, which found:

• Significantly increased dizziness risk (RR 1.64,95% CI 1.04 to 2.57) 3
• Higher risk in younger patients (≤60 years) based on subgroup analysis 3
• No significant increase in other neurological outcomes like headache or transient ischemic attack 3

Clinical Evaluation Approach

When a patient on Zepbound reports dizziness, systematically evaluate:

Immediate assessment priorities:

• Orthostatic vital signs - Check for postural hypotension related to volume depletion from gastrointestinal side effects or rapid weight loss
• Hydration status - Assess for dehydration secondary to nausea, vomiting, or diarrhea (present in 25-35% of patients) 2
• Glucose levels - Rule out hypoglycemia, especially if on concurrent diabetes medications 1
• Electrolytes - Check for hyponatremia, as SIADH has been reported with tirzepatide 4

Secondary considerations:

• Kidney function - Acute kidney injury can occur, particularly during dose escalation 1
• Medication interactions - Review all concurrent medications, as 44% of ADR cases involved polypharmacy 5
• Timing relative to dosing - Most ADRs occur within 1-6 months of initiation 5

Management Strategy

For mild-to-moderate dizziness:

1. Optimize hydration - Counsel on adequate fluid intake (particularly important given GI side effects)
2. Dietary modifications - Smaller meals, increased fiber, avoiding high-fat/spicy foods 2
3. Monitor closely - Many patients develop tolerance over time 2

For persistent or severe dizziness:

1. Dose reduction - Consider decreasing from 15 mg to 10 mg or lower, as demonstrated effective in case reports 6
2. Temporary discontinuation - If symptoms are significantly impacting quality of life
3. Re-challenge cautiously - One case showed symptom recurrence with re-escalation 6

Red flags requiring immediate evaluation:

• Altered mental status or confusion (consider rare limbic encephalitis 4)
• Severe headache with visual changes (consider NAION 7)
• Chest pain or palpitations (evaluate cardiac function and thyroid status 8)
• Severe abdominal pain (rule out pancreatitis, gallbladder disease 2)

Important Clinical Pitfalls

Do not dismiss dizziness as benign - While gastrointestinal effects dominate the safety profile in guidelines 1, 2, emerging evidence shows dizziness is a real and quantifiable risk 3. The retrospective analysis of 43 ADR cases identified several serious neurological events not mentioned in prescribing information, including common peroneal neuropathy and even limbic encephalitis 5, 4.

Age matters - Younger patients (≤60 years) appear at higher risk for dizziness 3, contrary to typical assumptions about medication tolerance.

Volume status is critical - The combination of reduced oral intake (from appetite suppression), GI losses (from nausea/vomiting/diarrhea), and rapid weight loss creates a perfect storm for orthostatic symptoms.

Monitoring Recommendations

For patients continuing tirzepatide with dizziness:

• Weekly symptom assessment during first month
• Orthostatic vital signs at each visit
• Renal function and electrolytes at baseline and with dose changes 1
• Consider dose reduction rather than discontinuation to preserve weight loss benefits 6

The evidence supports that dose reduction can resolve dizziness while maintaining therapeutic weight loss, as demonstrated in multiple case reports where patients maintained weight reduction despite lower doses 6.